| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| tralokinumab | interleukin-13 | biotech | Clinical trial target | TTD , drugbank , DGIDB | Eczema[MeSHID:D004485] Dermatitis Atopic[MeSHID:D003876] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Ulcerative Colitis[MeSHID:D003093] Asthma[MeSHID:D001249] |
11.93 | approved,investigational,phase 3 | antibody,inhibitor |
| tralokinumab | interleukin-13 | biotech | Clinical trial target | TTD , drugbank , DGIDB | Eczema[MeSHID:D004485] Dermatitis Atopic[MeSHID:D003876] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Ulcerative Colitis[MeSHID:D003093] Asthma[MeSHID:D001249] |
11.93 | approved,investigational,phase 3 | antibody |
| tralokinumab | interleukin 13 receptor alpha-2 | NA | Clinical trial target | TTD , DGIDB | Eczema[MeSHID:D004485] Dermatitis Atopic[MeSHID:D003876] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Ulcerative Colitis[MeSHID:D003093] Asthma[MeSHID:D001249] |
10.61 | phase 3 | unknown |
| click here to return to the previous page | ||||||||